

Declaration of Interests Register

TA Committee C

Publication Date: 12/05/2021

Topic: Tafamidis for treating transthyretin amyloid cardiomyopathy

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Andrea Manca	TAC C Committee Member	Financial Interests	Received consultancy fee from manufacturer for participation in an Advisory Board relating to this product	07/05/2020	07/05/2020	N/A	Professor Andrea Manca excused himself from this meeting on grounds of confliction.
Matthew Stevenson	TAC C Committee Member	Non-financial Professional & Personal Interests	Director of ScHARR-TAG, the ERG for this appraisal.	07/05/2020	07/05/2020	N/A	It was agreed that this declaration would not prevent Matt Stevenson from participating in this section of the meeting and noted that he will not be a voting member on this appraisal.
Perry Elliott	Clinical Expert	Financial & Non-financial Interests	Advisory boards and speaker fees for Pfizer & Alnylam. Unrestricted educational grant, Pfizer. President of Cardiomyopathy UK, a national charity for people with cardiomyopathies. PI on following trials:	13/07/2020	13/07/2020	N/A	N/A

			<p>B3461028: A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM).</p> <p>B3461045 - a phase 3 multicenter, open-label study to evaluate the safety of daily oral dosing of tafamidis meglumine (pf-06291826-83) 20 mg or 80 mg [or tafamidis (pf-06291826-00) 61 mg] in subjects diagnosed with transthyretin cardiomyopathy (ATTR-CM)</p> <p>TTRACK: prevalence and characteristics of transthyretin amyloidosis in patients with left ventricular hypertrophy of unknown etiology (Pfizer).</p>				
--	--	--	---	--	--	--	--

			Helios-b: a phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (attr amyloidosis with cardiomyopathy). (AInylam)				
Prithwiraj Das	TAC C Committee Member	non-financial & personal Interest	Works at Boehringer Ingelheim as the Market Access Lead on Speciality Medicines (oncology, inflammation, thrombolysis). However, has not worked on any of these indications in the last 12 months.	01/09/2020	01/09/2020	N/A	It was agreed that this declaration <u>would not</u> prevent Prithwiraj from participating in the meeting.